ES2613667T3 - Composiciones farmacéuticas que comprenden un inhibidor de aromatasa - Google Patents
Composiciones farmacéuticas que comprenden un inhibidor de aromatasa Download PDFInfo
- Publication number
- ES2613667T3 ES2613667T3 ES12758966.1T ES12758966T ES2613667T3 ES 2613667 T3 ES2613667 T3 ES 2613667T3 ES 12758966 T ES12758966 T ES 12758966T ES 2613667 T3 ES2613667 T3 ES 2613667T3
- Authority
- ES
- Spain
- Prior art keywords
- capsule
- weight
- amount
- disintegrant
- lubricant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229940122815 Aromatase inhibitor Drugs 0.000 title 1
- 239000003886 aromatase inhibitor Substances 0.000 title 1
- 239000002775 capsule Substances 0.000 abstract description 16
- 239000000203 mixture Substances 0.000 abstract description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 abstract description 4
- 125000003626 1,2,4-triazol-1-yl group Chemical group [*]N1N=C([H])N=C1[H] 0.000 abstract description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 abstract description 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract description 3
- 229940079832 sodium starch glycolate Drugs 0.000 abstract description 3
- 239000008109 sodium starch glycolate Substances 0.000 abstract description 3
- 229920003109 sodium starch glycolate Polymers 0.000 abstract description 3
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 abstract description 2
- 229920002261 Corn starch Polymers 0.000 abstract description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract description 2
- 239000008120 corn starch Substances 0.000 abstract description 2
- 229940099112 cornstarch Drugs 0.000 abstract description 2
- 229960001021 lactose monohydrate Drugs 0.000 abstract description 2
- 235000019359 magnesium stearate Nutrition 0.000 abstract description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract description 2
- 239000008108 microcrystalline cellulose Substances 0.000 abstract description 2
- 239000007884 disintegrant Substances 0.000 abstract 3
- 239000000314 lubricant Substances 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 abstract 1
- PZDLRBUQYWMNBR-UHFFFAOYSA-N 4-[(4-cyanophenyl)-fluoro-(1,2,4-triazol-1-yl)methyl]benzonitrile Chemical compound C=1C=C(C#N)C=CC=1C(N1N=CN=C1)(F)C1=CC=C(C#N)C=C1 PZDLRBUQYWMNBR-UHFFFAOYSA-N 0.000 description 11
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 3
- 229960003881 letrozole Drugs 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 2
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 239000000328 estrogen antagonist Substances 0.000 description 2
- 229960003399 estrone Drugs 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- JKKFKPJIXZFSSB-UHFFFAOYSA-N 1,3,5(10)-estratrien-17-one 3-sulfate Natural products OS(=O)(=O)OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 JKKFKPJIXZFSSB-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- TVEXGJYMHHTVKP-UHFFFAOYSA-N 6-oxabicyclo[3.2.1]oct-3-en-7-one Chemical compound C1C2C(=O)OC1C=CC2 TVEXGJYMHHTVKP-UHFFFAOYSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- JKKFKPJIXZFSSB-CBZIJGRNSA-N estrone 3-sulfate Chemical compound OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JKKFKPJIXZFSSB-CBZIJGRNSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Reproductive Health (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Gynecology & Obstetrics (AREA)
- Nutrition Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Dermatology (AREA)
- Pregnancy & Childbirth (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161532459P | 2011-09-08 | 2011-09-08 | |
| US201161532459P | 2011-09-08 | ||
| US201261638588P | 2012-04-26 | 2012-04-26 | |
| US201261638588P | 2012-04-26 | ||
| PCT/US2012/053846 WO2013036563A1 (en) | 2011-09-08 | 2012-09-06 | Pharmaceutical compositions comprising an aromatase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2613667T3 true ES2613667T3 (es) | 2017-05-25 |
Family
ID=46846026
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12758966.1T Active ES2613667T3 (es) | 2011-09-08 | 2012-09-06 | Composiciones farmacéuticas que comprenden un inhibidor de aromatasa |
| ES12758965.3T Active ES2613666T3 (es) | 2011-09-08 | 2012-09-06 | Uso de un inhibidor de aromatasa para el tratamiento del hipogonadismo y enfermedades relacionadas |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12758965.3T Active ES2613666T3 (es) | 2011-09-08 | 2012-09-06 | Uso de un inhibidor de aromatasa para el tratamiento del hipogonadismo y enfermedades relacionadas |
Country Status (31)
| Country | Link |
|---|---|
| US (4) | US9295668B2 (enExample) |
| EP (2) | EP2753313B1 (enExample) |
| JP (2) | JP6051467B2 (enExample) |
| KR (3) | KR20140071358A (enExample) |
| CN (2) | CN103796644B (enExample) |
| AR (1) | AR087790A1 (enExample) |
| AU (2) | AU2012304694B2 (enExample) |
| BR (2) | BR112014005434B1 (enExample) |
| CA (2) | CA2846884C (enExample) |
| CL (1) | CL2014000552A1 (enExample) |
| CY (2) | CY1118461T1 (enExample) |
| DK (2) | DK2753312T3 (enExample) |
| ES (2) | ES2613667T3 (enExample) |
| HR (2) | HRP20170003T1 (enExample) |
| HU (2) | HUE031478T2 (enExample) |
| IL (1) | IL231234A (enExample) |
| IN (1) | IN2014DN01619A (enExample) |
| LT (2) | LT2753312T (enExample) |
| MX (2) | MX343902B (enExample) |
| PE (1) | PE20141584A1 (enExample) |
| PH (1) | PH12014500435A1 (enExample) |
| PL (2) | PL2753313T3 (enExample) |
| PT (2) | PT2753313T (enExample) |
| RU (2) | RU2617510C2 (enExample) |
| SG (2) | SG2014012132A (enExample) |
| SI (2) | SI2753312T1 (enExample) |
| TN (1) | TN2014000059A1 (enExample) |
| TW (1) | TW201316987A (enExample) |
| UY (1) | UY34315A (enExample) |
| WO (2) | WO2013036562A1 (enExample) |
| ZA (1) | ZA201401040B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2753312T1 (sl) * | 2011-09-08 | 2017-10-30 | Mereo Biopharma 2 Limited | Uporaba inhibitorja aromataze za zdravljenje hipogonadizma in sororodnih bolezni |
| WO2015148549A1 (en) * | 2014-03-26 | 2015-10-01 | The Regents Of The University Of California | Ultrasensitive androgen receptor bioassay |
| PT3166596T (pt) * | 2014-07-07 | 2018-10-19 | Novartis Ag | Formas farmacêuticas |
| GB201614179D0 (en) * | 2016-08-19 | 2016-10-05 | Mereo Biopharma 2 Ltd | Dosage regimen for the treatment of endometriosis |
| JP2020510027A (ja) * | 2017-03-08 | 2020-04-02 | アリアド ファーマシューティカルズ，インコーポレーテッド | ５−クロロ−ｎ４−［２−（ジメチルホスホリル）フェニル］−ｎ２−｛２−メトキシ−４−［４−（４−メチルピペラジン−１−イル）ピペリジン−１−イル］フェニル｝ピリミジン−２，４−ジアミンを含む医薬製剤 |
| CA3078652A1 (en) | 2017-10-12 | 2019-04-18 | Novo Nordisk A/S | Semaglutide in medical therapy |
| USD894149S1 (en) * | 2018-08-16 | 2020-08-25 | Alibaba Group Holding Limited | Information terminal for payment |
| USD894148S1 (en) * | 2018-08-16 | 2020-08-25 | Alibaba Group Holding Limited | Information terminal for payment |
| JP7121999B2 (ja) * | 2019-09-26 | 2022-08-19 | 学校法人九州文化学園 | 男性性腺機能低下症治療剤 |
| US12552754B1 (en) | 2025-06-11 | 2026-02-17 | ReproNovo SA | Leflutrozole compositions of matter and processes for preparation |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4749713A (en) | 1986-03-07 | 1988-06-07 | Ciba-Geigy Corporation | Alpha-heterocycle substituted tolunitriles |
| TW210334B (enExample) * | 1990-12-12 | 1993-08-01 | Ciba Geigy Ag | |
| DE4435368A1 (de) * | 1994-09-22 | 1996-03-28 | Schering Ag | Verwendung von Aromatasehemmern zur Herstellung eines Arzneimittels zur Behandlung eines relativen Androgenmangels beim Mann |
| US5972921A (en) * | 1997-12-12 | 1999-10-26 | Hormos Medical Oy Ltd. | Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men |
| AU2001271162A1 (en) * | 2000-07-05 | 2002-01-14 | Astrazeneca Ab | Pharmaceutical combination of an anti-androgen and letrozole for providing an anit-androgenic effect and aromatase inhibition |
| SK14252003A3 (sk) | 2001-04-17 | 2004-03-02 | Ares Trading S. A. | Použitie aromatázového inhibítora, farmaceutický prostriedok s obsahom aromatázového inhibítora a farmaceutické balenie |
| US7101573B2 (en) * | 2001-09-28 | 2006-09-05 | Mcneil-Pcc, Inc. | Simethicone solid oral dosage form |
| AU2003213957A1 (en) | 2002-04-03 | 2003-10-13 | Jencap Research Ltd. | Pharmaceutical composition comprising an aromatase inhibitor and an estrogen suitable for hormone replacement therapy for a male |
| WO2006114702A2 (en) | 2005-04-25 | 2006-11-02 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor |
| CN102335219A (zh) * | 2007-11-21 | 2012-02-01 | 客乐谐制药株式会社 | 芳香酶抑制剂 |
| SI2753312T1 (sl) * | 2011-09-08 | 2017-10-30 | Mereo Biopharma 2 Limited | Uporaba inhibitorja aromataze za zdravljenje hipogonadizma in sororodnih bolezni |
-
2012
- 2012-09-06 SI SI201230850T patent/SI2753312T1/sl unknown
- 2012-09-06 PL PL12758966T patent/PL2753313T3/pl unknown
- 2012-09-06 PT PT127589661T patent/PT2753313T/pt unknown
- 2012-09-06 RU RU2014113575A patent/RU2617510C2/ru active
- 2012-09-06 BR BR112014005434-7A patent/BR112014005434B1/pt active IP Right Grant
- 2012-09-06 ES ES12758966.1T patent/ES2613667T3/es active Active
- 2012-09-06 AR ARP120103283A patent/AR087790A1/es unknown
- 2012-09-06 HU HUE12758965A patent/HUE031478T2/hu unknown
- 2012-09-06 RU RU2014113334A patent/RU2628808C2/ru active
- 2012-09-06 EP EP12758966.1A patent/EP2753313B1/en active Active
- 2012-09-06 KR KR1020147006170A patent/KR20140071358A/ko not_active Ceased
- 2012-09-06 PT PT127589653T patent/PT2753312T/pt unknown
- 2012-09-06 AU AU2012304694A patent/AU2012304694B2/en active Active
- 2012-09-06 JP JP2014529833A patent/JP6051467B2/ja active Active
- 2012-09-06 CA CA2846884A patent/CA2846884C/en active Active
- 2012-09-06 MX MX2014002773A patent/MX343902B/es active IP Right Grant
- 2012-09-06 CN CN201280043378.9A patent/CN103796644B/zh active Active
- 2012-09-06 SG SG2014012132A patent/SG2014012132A/en unknown
- 2012-09-06 LT LTEP12758965.3T patent/LT2753312T/lt unknown
- 2012-09-06 IN IN1619DEN2014 patent/IN2014DN01619A/en unknown
- 2012-09-06 EP EP12758965.3A patent/EP2753312B1/en active Active
- 2012-09-06 KR KR1020187007058A patent/KR20180030254A/ko not_active Ceased
- 2012-09-06 DK DK12758965.3T patent/DK2753312T3/da active
- 2012-09-06 PL PL12758965T patent/PL2753312T3/pl unknown
- 2012-09-06 PE PE2014000325A patent/PE20141584A1/es not_active Application Discontinuation
- 2012-09-06 US US14/342,810 patent/US9295668B2/en active Active
- 2012-09-06 MX MX2014002780A patent/MX360315B/es active IP Right Grant
- 2012-09-06 HU HUE12758966A patent/HUE031435T2/en unknown
- 2012-09-06 US US14/342,813 patent/US9370505B2/en active Active
- 2012-09-06 LT LTEP12758966.1T patent/LT2753313T/lt unknown
- 2012-09-06 CN CN201280043614.7A patent/CN103781476B/zh active Active
- 2012-09-06 BR BR112014004879A patent/BR112014004879B1/pt active IP Right Grant
- 2012-09-06 KR KR1020147006171A patent/KR101872561B1/ko active Active
- 2012-09-06 SG SG10201607503WA patent/SG10201607503WA/en unknown
- 2012-09-06 CA CA2845929A patent/CA2845929C/en active Active
- 2012-09-06 WO PCT/US2012/053844 patent/WO2013036562A1/en not_active Ceased
- 2012-09-06 HR HRP20170003TT patent/HRP20170003T1/hr unknown
- 2012-09-06 PH PH1/2014/500435A patent/PH12014500435A1/en unknown
- 2012-09-06 JP JP2014529832A patent/JP6280501B2/ja active Active
- 2012-09-06 DK DK12758966.1T patent/DK2753313T3/en active
- 2012-09-06 HR HRP20170002TT patent/HRP20170002T1/hr unknown
- 2012-09-06 WO PCT/US2012/053846 patent/WO2013036563A1/en not_active Ceased
- 2012-09-06 ES ES12758965.3T patent/ES2613666T3/es active Active
- 2012-09-06 AU AU2012304693A patent/AU2012304693B2/en active Active
- 2012-09-06 SI SI201230848A patent/SI2753313T1/sl unknown
- 2012-09-07 TW TW101132840A patent/TW201316987A/zh unknown
- 2012-09-10 UY UY0001034315A patent/UY34315A/es not_active Application Discontinuation
-
2014
- 2014-02-10 TN TNP2014000059A patent/TN2014000059A1/en unknown
- 2014-02-11 ZA ZA2014/01040A patent/ZA201401040B/en unknown
- 2014-02-27 IL IL231234A patent/IL231234A/en active IP Right Grant
- 2014-03-07 CL CL2014000552A patent/CL2014000552A1/es unknown
-
2016
- 2016-02-22 US US15/050,394 patent/US9750724B2/en active Active
- 2016-05-27 US US15/167,867 patent/US10064844B2/en active Active
-
2017
- 2017-01-18 CY CY20171100074T patent/CY1118461T1/el unknown
- 2017-01-24 CY CY20171100100T patent/CY1118499T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2967709T3 (es) | Formulaciones y terapias naturales de reemplazo hormonal combinadas | |
| KR101872561B1 (ko) | 아로마타제 억제제를 포함하는 제약 조성물 | |
| JP7433252B2 (ja) | Ｎｋ－１／ｎｋ－３受容体二重アンタゴニストを含む新規な医薬製剤 | |
| BR112012025961B1 (pt) | Composição farmacêutica oral | |
| ES2237408T3 (es) | Antiandrogenos y procedimientos para tratar una enfermedad. | |
| KR102238478B1 (ko) | 구강 전달용 지방균형잡힌 장쇄 테스토스테론 에스테르 | |
| US20190192485A1 (en) | Dosage regimen for the treatment of endometriosis | |
| BR122025016695A2 (pt) | Usos de drospirenona, composição farmacêutica e kit de drospirenona | |
| AU2017223595A1 (en) | An improved formulation of long-acting levonorgestrel butanoate injectable depot suspension | |
| US20200069702A1 (en) | Oral pharmaceutical compositions comprising an unmicronized selective progesterone receptor as active agent | |
| WO2014048511A1 (en) | Metadoxine for use in the treatment of liver diseases, and metadoxine extended release formulations | |
| BR122024026592A2 (pt) | Formulação farmacêutica de cápsula de gelatina mole compreendendo antagonistas duplos dos receptores nk-1/nk-3, seu uso e seu método de preparação | |
| BR112016009008B1 (pt) | Uso de estradiol e/ou hemi-hidrato de estradiol e de um agente solubilizante compreendendo um óleo de cadeia média para a preparação de um pessário para o tratamento de atrofia vulvovaginal e pessário que compreende estradiol | |
| TW200306197A (en) | Medicament for treating climacteric post-menopausal complaints | |
| TW200942242A (en) | New drospirenone/17β-estradiol regimen, pharmaceutical combination product and kit for performing this regimen | |
| JP2000159688A (ja) | 子宮内膜症の処置又は予防剤 |